Tier 3 — preclinical

The Therapeutic Potential of Apigenin

Salehi B, Venditti A, Sharifi-Rad M, Kregiel D, Sharifi-Rad J, Durazzo A, Lucarini M, Santini A, Souto EB, Novellino E, Antolak H, Azzini E, Setzer WN, Martins N
International Journal of Molecular Sciences 2019 20(6):1305

Bibliography

PubMed
PMID 30875872
DOI
10.3390/ijms20061305
Funding
Not stated in the available abstract.
Competing interests
Not stated in the available abstract.

Study snapshot

DesignNarrative review
ModelMixed: in vivo animal models and human studies summarised
SampleNot applicable (review)
InterventionNot applicable (review of existing apigenin literature)
DurationNot applicable (review)
EndpointsDiabetes-related outcomes; Cognitive/Alzheimer's-related outcomes; Depression and insomnia; Cancer-related outcomes; Dietary exposure assessment

What the study showed, in plain terms

This review summarises what's known about apigenin's health effects, drawing mainly on animal research with some human studies included. It covers potential benefits in diabetes, memory and Alzheimer's disease, depression and sleep, and cancer, while noting that most of the strongest evidence still comes from animal models rather than completed human trials.

Key findings

Apigenin, one of the most common dietary flavonoids, shows a wide range of biological activities in preclinical research, including effects relevant to diabetes, amnesia and Alzheimer's disease, depression and insomnia, and cancer. The review's key findings are drawn primarily from in vivo animal research, with human study data described as more limited by comparison.

What this study can and cannot tell us

As a narrative review rather than a systematic review or meta-analysis, it does not apply formal inclusion criteria or quality grading. Most in vivo evidence discussed is from animal models rather than completed human randomised trials.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology